Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains

Neuroscience

Volumn 231, Issue , 2013, Pages 157-168

  Piltonen, M ^a   Savolainen, M ^a   Patrikainen, S ^a   Baekelandt, V ^b   Myohanen T T ^a   Mannisto P T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

6 OHDA; Alpha synuclein; Behavior; Dopamine; Transgenic

Indexed keywords

A30P ALPHA SYNUCLEIN; ALPHA SYNUCLEIN; DEXAMPHETAMINE; DOPAMINE; HOMOVANILLIC ACID; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; GENE EXPRESSION; GENE MUTATION; GENETIC DIFFERENCE; HISTOLOGY; HOMOZYGOSITY; LOCOMOTION; MOTOR PERFORMANCE; MOUSE; MOUSE STRAIN; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GAIT; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS;

EID: 84871946790     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.11.045     Document Type: Article

References (37)

1. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252.
2. Airavaara M., Mijatovic J., Vihavainen T., Piepponen T.P., Saarma M., Ahtee L. In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 2006, 59:321-329.
3. Bodner C.R., Maltsev A.S., Dobson C.M., Bax A. Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry 2010, 49:862-871.
4. Burre J., Sharma M., Sudhof T.C. Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci 2012, 32:15227-15242.
5. Bussell R., Eliezer D. Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein. Biochemistry 2004, 43:4810-4818.
6. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
7. Cleren C., Naudin B., Costentin J. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons. Brain Res 2003, 989:187-195.
8. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998, 4:1318-1320.
9. Fernagut P.O., Diguet E., Labattu B., Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods 2002, 113:123-130.
10. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004, 24:6715-6723.
11. Gomez-Isla T., Irizarry M.C., Mariash A., Cheung B., Soto O., Schrump S., Sondel J., Kotilinek L., Day J., Schwarzschild M.A., Cha J.H., Newell K., Miller D.W., Ueda K., Young A.B., Hyman B.T., Ashe K.H. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2003, 24:245-258.
12. Howells D.W., Liberatore G.T., Wong J.Y., Donnan G.A. Dopaminergic responses to striatal damage. J Neurol Sci 1996, 139:125-130.
13. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
14. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G., Goedert M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem 1998, 273:26292-26294.
15. Jo E., Fuller N., Rand R.P., St George-Hyslop P., Fraser P.E. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol Biol 2002, 315:799-807.
16. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998, 18:106-108.
17. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002, 99:8968-8973.
18. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S., Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001, 8:535-539.
19. Melamed E., Hefti F., Wurtman R.J. Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. Proc Natl Acad Sci U S A 1980, 77:4305-4309.
20. Mijatovic J., Airavaara M., Planken A., Auvinen P., Raasmaja A., Piepponen T.P., Costantini F., Ahtee L., Saarma M. Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J Neurosci 2007, 27:4799-4809.
21. Myöhänen T.T., Venäläinen J.I., Garcia-Horsman J.A., Piltonen M., Männistö P.T. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol 2008, 507:1694-1708.
22. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999, 274:9843-9846.
23. Nieto M., Gil-Bea F.J., Dalfo E., Cuadrado M., Cabodevilla F., Sanchez B., Catena S., Sesma T., Ribe E., Ferrer I., Ramirez M.J., Gomez-Isla T. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol Aging 2006, 27:848-856.
24. Oksman M., Tanila H., Yavich L. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of l-DOPA. Neuropharmacology 2009, 56:647-652.
25. Plaas M., Karis A., Innos J., Rebane E., Baekelandt V., Vaarmann A., Luuk H., Vasar E., Kõks S. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice. J Physiol Pharmacol 2008, 59:205-216.
26. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
27. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C., Schulz J.B. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem 2001, 77:1181-1184.
28. Sidhu A., Wersinger C., Moussa C.E., Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 2004, 1035:250-270.
29. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
30. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
31. Surguchov A. Molecular and cellular biology of synucleins. Int Rev Cell Mol Biol 2008, 270:225-317.
32. Szego E.M., Gerhardt E., Kermer P., Schulz J.B. A30P alpha-synuclein impairs dopaminergic fiber regeneration and interacts with l-DOPA replacement in MPTP-treated mice. Neurobiol Dis 2012, 45:591-600.
33. Wersinger C., Prou D., Vernier P., Niznik H.B., Sidhu A. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol Cell Neurosci 2003, 24:91-105.
34. Wersinger C., Sidhu A. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry 2005, 44:13612-13624.
35. Yavich L., Oksman M., Tanila H., Kerokoski P., Hiltunen M., van Groen T., Puoliväli J., Männistö P.T., Garcia-Horsman A., MacDonald E., Beyreuther K., Hartmann T., Jäkälä P. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 2005, 20:303-313.
36. Yavich L., Tanila H., Vepsäläinen S., Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 2004, 24:11165-11170.
37. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004, 55:164-173.